The two protein exotoxins secreted by Bacillus anthracis are composed of three distinct components : protective antigen (PA), lethal factor (LF), and (o)edema factor (EF). We have developed a genetic strategy that permits us selectively to inactivate each of the genes coding for PA, EF or LF. This strategy involved the deletion of a portion of the structural gene and the insertion of an antibiotic resistance cassette. With this technique, double mutant strains of B. anthracis producing only one toxin component have been constructed. Characterization of the mutant strains indicated that they produced the expected single toxin protein. Using a simple, two-step protocol, we have purified PA, LF and EF to homogeneity from culture supernatants. These three mutant strains are potentially powerful tools for studying the individual effect of each toxin component in vitvo and in vivo.
Introduction
Bacillus anthracis, the aetiological agent of anthrax, secretes three separate proteinsprotective antigen (PA; 85 kDa), (o)edema factor (EF; 89 kDa) and lethal factor (LF; 83 kDa) -that make up the two anthrax toxins (Stanley & Smith, 1961; Fish et al., 19683; Leppla, 1984) . Individually, none of the three toxin components has any biological effect (Smith & Stoner, 1967) . PA combined with LF forms the lethal toxin whereas oedema toxin consists of PA and EF (Beall et al., 1962; Smith & Stoner, 1967) . PA is the common receptor-binding component mediating entry of either LF or EF into target cells (Leppla, 1984) . EF has been shown to be a calmodulin-dependent adenylate cyclase (Leppla, 1982) . The mode of action of LF remains unknown.
Fully virulent strains of B. anthracis possess two large plasmids, pX01 and pX02. pX02 codes for the formation of a poly-D-glutamic acid capsule (Avakyan et al., 1965; Uchida et al., 1985) , whereas toxin production is conferred by pXO1 (Mikesell et al., 1983 ) which carries the toxin structural genes. These three genes, pug, cya and leL coding for PA, EF and LF, respectively, have been cloned and sequenced (Bragg & Robertson, 1989; Escuyer et al., 1988; Mock et al., 1988; , thus providing the basis for genetic studies.
Most of the available data on toxin mode of action have been obtained with toxin components purified from culture supernatants of the Sterne strain (Beall et al., 1962; Fish et al., 1968a; Smith & Stoner, 1967) . Because of the difficulty in separating the three proteins from each other, several strategies have been developed in an attempt to increase purity. These approaches include multi-step chromatographic procedures (Leppla, 1988 ; Quinn et al., 1988) or expression in different bacterial systems (Vodkin & Leppla, 1983; Ivins & Welkos, 1986; Iacono-Connors et al., 1990) .
We have previously devised a genetic strategy allowing the construction of B. anthracis mutant strains deficient in one toxin component (Cataldi et al., 1990; Pezard et al., 1991) . We have extended this genetic approach to the construction of double mutant strains with the aim of producing PA, EF and LF as single toxin components from B. anthracis. Use of these mutant strains in toxin preparation precludes the possibility of cross-contamination by individual toxin components, and should prove to be a useful and convenient tool for purifying each protein to homogeneity. .
pAT28 (Trieu-Cuot et al., 1990 a) , conferring spectinomycin resistance (Spc? was used as the vector for transferring DNA into Bacillus anthracis strains. The mating procedure used for conjugal transfer of recombinant plasmids from E. coli to B. anthracis was as previously described (Pezard et al., 1991) .
E. coli was grown in L broth or L agar (Miller, 1972) , and B. anthracis was grown in brain-heart infusion (BHI) medium (Difco). Rmedium (Ristroph & Ivins, 1983) was used for toxin production. Antibiotics were used at the following concentrations : ampicillin, 100 pg ml-' for E. coli cultures; spectinomycin, 100 and 60 pg ml-' for E. coli and B. anthracis cultures, respectively; erythromycin, 180 and 10 pg ml-' for E. coli and B. anthracis cultures, respectively.
Spores of B. anthracis strains were prepared as previously described (Pezard et al., 1991) .
DNA techniques. pXOl was prepared by the method of Green et al. (1985) . Methods for recombinant DNA manipulations were as described by Sambrook et al. (1989) . DNA fragments were prepared from agarose gels using the Geneclean Kit (Bio 101). Recombinant plasmid pACP41, a pUC8 derivative which contains the 3-4 kb XhoI-BarnHI fragment carrying pug was used for construction of pCPA110. A 2.5 kb HincII deletion starting at position 1272 and stopping at 3759 (from the previously published pug nucleotide sequence, was created in pACP41 and the Erm' cassette was inserted into the HincII site. The resulting DNA fragment carrying pagA652 was then subcloned in the shuttle plasmid pAT28 yielding pCPA 1 10.
Southern blot DNA hybridizations were performed with Hybond-N+ nylon membranes (Amersham). DNA probes were labelled using the ECL labelling system (kit RPN3000, Amersham).
Protein analysis and adenylate cyclase assay. SDS-PAGE (8 YO, w/v, acrylamide) was performed as described by Laemmli (1 970) . Gels were stained with Coomassie blue or subjected to immunoblot analysis (Towbin et al., 1979) . Western blots (immunoblots) were probed with rabbit sera raised against LF or PA purified from polyacrylamide gels or against a truncated form of EF (CYA 62) (Labruykre et al., 1990) .
Adenylate cyclase was assayed in B. anthracis R-medium culture supernatants as previously described (Ladant, 1988) . Enzymic activity is expressed in units ml-'. One unit corresponds to 1 nM-CAMP formed in 1 min at 30 "C.
PuriJication of toxin components. Toxin components were prepared from B. anthracis mutant strains as follows. Colonies freshly grown on BH1/5% (v/v) blood agar were used to inoculate 500 ml R-medium (Ristroph & Ivins, 1983 ) in a 1 litre flask. Cultures were grown at 37 "C for 15 h without shaking in an atmosphere of 5 % (v/v) CO,. Culture supernatants (4 1) were filtered through a 0.45 pm pore-size membrane (Nalgene). The cell-free filtrate was concentrated 40-fold by ultrafiltration through PTGC membranes (molecular mass cut-off, 10000 Da) in a Minitan system (Millipore). Protein was precipitated overnight at 4 "C by the addition of (NH,),SO, to 70 '30 saturation. The precipitate was collected by centrifugation at 35000 g for 30 min and resuspended in 2 ml10 mM-Tris/HC1 pH 8.0. Crude toxin preparations were desalted by dialysis, and further purified by anion-exchange chromatography over a Mono Q HR 5/5 column (FPLC, Pharmacia LKB), with 10 mM-Tris/HCl buffer pH 8.0 and a linear NaCl gradient as described by Quinn et al. (1988) .
Infection of mice. Female, six-week-old, pathogen-free Swiss mice were supplied by Charles River (Saint-Aubin-les Elbeuf, France) and used for determination of the lethal dose (LD,,) of each strain, as described previously (Pezard et al., 1991) .
Results and Discussion
Construction and characterization of double mutant B. anthracis strains
We have described previously a genetic strategy for the construction of B. anthracis mutant strains deficient in the production of PA (RP8), EF (RP9), or LF (RP10). The toxin genes pug, cya and lef were inactivated by intragenic deletion and insertion of an antibiotic resistance cassette (Em' or Kan'), allowing selection of recombinant strains carrying mutated genes on pXOl IP: 54.70.40.11
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PuriJication of toxin components of B. anthracis 2461 (Cataldi et al., 1990; Pezard et al., 1991) . We have now extended this approach and constructed double mutant strains capable of producing only a single toxin component. For this work, two recombinant plasmids derived from pAT28 were constructed. pCPA110 carries the pug gene inactivated through deletion and insertion of a DNA cassette conferring erythromycin resistance (Erm'). pMMAl11 carries the cya gene inactivated in the same manner (cyaA303) as that described previously for pMMA110 (Pezard et al., 1991) , except that an Erm' cassette was inserted in the gene. Mutants RP9 and RPlO were used as recipient strains for subsequent inactivation of a second toxin gene (Table 1) .
pCPAllO was transferred by conjugation to RP9 or RP10. The resulting transconjugants were cultured in the absence of spectinomycin (selective antibiotic for the vector part of pCPA110) and in the presence of erythromycin (selecting for the maintenance of the cassette), to select Erm' Spc' clones which presumably had lost pCPAllO but integrated the inactivated pug gene into pXOl by homologous recombination. Two strains, RP4 and RP3 1, which originated from recipient strains RP9 and RP10, respectively, were isolated. A third Erm'Spcs strain, RP42, was isolated from an RPlOderived transconjugant carrying recombinant plasmid pMMA111. Strains RP4, RP3 1 and RP42 were expected to produce only LF, EF or PA, respectively, after replacement of wild-typepag (RP4, RP31) or cya (RP42). The recombinant pXO1 from the three mutant strains was subjected to restriction analysis.
The cya gene is located on a 7.0 kb BamHI fragment of pXO1 (Mock et al., 1988) . A BamHI digest of pXO1 originating from RP42 was cloned into pUC18 and recombinant plasmids able to confer Erm' in E. coli were isolated. These plasmids contained a 7.0 kb BamHI fragment and restriction enzyme analysis indicated that the BamHI fragment carried inactivated cyaA303 E' ( Table 1) .
The pug gene is located on a 6.0 kb BamHI fragment of pXOl (Vodkin & Leppler, 1983) . Since the Erm' cassette inserted in the gene was flanked by two BamHI sites, this enzyme could not be used for cloning inactivated pagA652. We expected pagA652 to be located on a HindIII fragment of pXO1 larger than 3-0 kb. Therefore, we cloned HindIII digests of recombinant pXO1 originating from RP4 and RP31 into pUC18. In both cases, Erm' E. coli transformants were isolated. Their respective recombinant pUC derivative plasmids carried a 4.0 kb HindIII fragment containing the expected pagA652 construction as determined by restriction enzyme analysis.
The location of the E m ' cassette on the three recombinant pX0 1 plasmids was further characterized by Southern blot analysis. As shown in Fig. 1, a 7 .0 kb fragment from a BamHI digest of pXOl from RP42 (lane 2) and a 4.0 kb fragment from a HindIII digest of pX0 1 from RP3 1 or RP4 (lanes 4 and 5) hybridized with the E m ' cassette when it was used as a probe. These results confirmed that for all three B. anthracis recombinants the Erm'cassette was located on pXOl, within the pug coding sequence for RP4 and RP31 and within the cya coding sequence for RP42. We therefore concluded that we had constructed three mutant strains in which two of the three toxin components genes were inactivated. These strains were therefore expected to produce only one toxin component: EF from RP31, LF from RP4, and PA from RP42.
Production of toxin proteins in mutant strains of B. anthracis
The anthrax toxin components PA, EF and LF are produced by B. anthracis when bacteria are grown in Rmedium (Ristroph & Ivins, 1983) and constitute the most abundant extracellular proteins (Fig. 2, lane 1) . Analysis of the culture supernatants of each mutant strain, RP42, RP31 and RP4, indicated the presence of a major species of protein (Fig. 2, lanes 2, 3 and 4) ; these proteins were further characterized by Western blot analysis using specific antisera raised against PA, EF or LF. The supernatant proteins of strains RP42, RP31 and RP4 were exclusively immunodetected with anti-PA, anti-EF, and anti-LF sera respectively (data not shown). These results confirmed that, as expected, each strain produced only one of the three toxin components.
It is known that EF is an adenylate cyclase (Leppla, 1982) . To verify inactivation of the cya gene we determined adenylate cyclase activity in the culture supernatant of the three mutant strains and of parental strain 7702. No enzymic activity was detected in the supernatant of strain RP42 (PA+), thus confirming inactivation of the cya gene. As expected, strain RP4 (LF+) derived from W 9 , was also devoid of this activity. The adenylate cyclase activity found in the culture supernatant of RP31 (EF+) was similar to that of wildtype strain 7701 (200 Uml-') under the same experimental conditions. Growth of RP4, RP31 and RP42 in large culture volumes allowed us to develop a purification procedure for recovery of each toxin component. Individual toxin components are produced by the corresponding mutant strain in quantities similar to those produced by the parental strain, 7702. Each protein was thus readily available at a high degree of purity with a simple twostep purification protocol (see Methods).
Virulence of B. anthracis mutant strains in mice
The virulence of the three B. anthracis mutants was studied in mice. The strains constructed in tlus work are derived from RP9 and WlO, whose virulence properties have been described previously (Pezard et al., 1991) .
Strain RP9 producing lethal toxin (PA + LF) causes death in mice at an LD,, of lo7. The inactivation of pug in mutant RP4 abolished the lethal effect of RP9, and inoculation of mice with lo9 spores of RP4 failed to provoke mortality. Strain RP 10, producing oedema toxin (PA+EF) has no lethal effect but still induces oedema in mice after subcutaneous injection. The inactivation of pug and cya in RP31 and RP42, respectively, abolished oedema formation after subcutaneous injection of lo9 spores. Therefore, the three mutant strains we have constructed, RP4, RP42 and RP3 1, producing only LF, PA, or EF, respectively, are avirulent and totally devoid of biological effect. These results demonstrate that individually none of the three proteins secreted by the bacteria is toxic for animals, and they are consistent with previous observation obtained after injection of the proteins into animals (Smith & Stoner, 1967) .
The Sterne strain, which carries only pXO1, is toxigenic and uncapsulated and is currently used as the veterinary vaccine against anthrax (Hambleton et aE., 1984; Sterne, 1939; Welkos & Friedlander, 1988b) . However, since this strain still produces both lethal and oedema toxins it is pathogenic to animals at high doses.
Mutant strains totally devoid of lethality might contribute to an improved live vaccine. Further studies with our mutant strains should provide new insights into B. anthracis pathogenesis as well as into immunization against anthrax. While it is well known that PA is the main toxin component required for protection of animals and humans (Hambleton et al., 1984; Welkos & Friedlander, 1988a) , the contribution of EF and LF to the immune response remains unclear. Investigation of the protective efficacy of these strains should help to clarify the respective roles of the individual toxin components in protection against anthrax.
